Evidence map›Paper›PMID 33637020›Full record

Trial reportThyroid : official journal of the American Thyroid Association2021

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.

Matthew H Taylor, Shunji Takahashi, Jaume Capdevila, Makoto Tahara, Sophie Leboulleux, Naomi Kiyota, Corina E Dutcus, Ran Xie, Bruce Robinson, Steven Sherman and 3 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Thyroid : official journal of the American Thyroid Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Neutrophil-To-Lymphocyte Ratio as a Prognostic Indicator in Thyroid Cancer.Cancer control : journal of the Moffitt Cancer Center
    Pooled it
  4. Trial
  5. Article
  6. Real-world experience of clinicopathological features and survival predictors in radioactive iodine-refractory differentiated thyroid cancer treated with multi-kinase inhibitors: a multicentre study from southeastern Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. BRAFThyroid research · 2025
    Article
  12. Management of follicular thyroid carcinoma.European thyroid journal · 2024
    Review
  13. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Matthew H TaylorEarle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA.
Shunji TakahashiDepartment of Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Jaume CapdevilaMedical Oncology Department, University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Makoto TaharaDivision of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Sophie LeboulleuxDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France.
Naomi KiyotaDepartment of Medical Oncology and Hematology and Cancer Center, Kobe University Hospital, Kusunoki Cho, Chuo-ku, Japan.
Corina E DutcusEisai Inc., Woodcliff Lake, New Jersey, USA.
Ran XieDepartment of Biostatistics, Eisai Inc., Woodcliff Lake, New Jersey, USA.
Bruce RobinsonRoyal North Shore Hospital, University of Sydney, Australia.
Steven ShermanDepartment of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Mouhammed Amir HabraDepartment of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Rossella EliseiEndocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Lori J WirthDepartment of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukocyte CountLymphocyte CountNeutrophilsAdultAgedAged, 80 and overAntineoplastic AgentsDouble-Blind MethodFemaleHumansIodine RadioisotopesMaleMiddle AgedPhenylurea CompoundsProgression-Free SurvivalProtein Kinase InhibitorsAntineoplastic AgentsIodine RadioisotopeslenvatinibPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesdifferentiated thyroid cancerECOGlenvatinibNLRtumor size

Identifiers

PMID33637020
PMCPMC8377516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.